Clancy J. Paul's most recent trade in Incyte Corp. was a trade of 252 Common Stock done at an average price of $113.4 . Disclosure was reported to the exchange on June 30, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 113.36 per share. | 30 Jun 2026 | 252 | 25,635 (0%) | 0% | 113.4 | 28,567 | Common Stock |
| Sionna Therapeutics Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2026 | 17,340 | 17,340 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2026 | 6,111 | 6,111 | - | - | Non Qualfied Stock Option (right to buy) | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2026 | 1,642 | 25,383 (0%) | 0% | 0 | Common Stock | |
| Incyte | Paul J. Clancy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2026 | 15,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte | Paul J. Clancy | Director | Sale of securities on an exchange or to another person at price $ 94.93 per share. | 19 May 2026 | 15,000 | 23,741 (0%) | 0% | 94.9 | 1,423,950 | Common Stock |
| Incyte | Paul J. Clancy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.53 per share. | 19 May 2026 | 15,000 | 38,741 (0%) | 0% | 84.5 | 1,267,950 | Common Stock |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 94.12 per share. | 31 Mar 2026 | 265 | 23,741 (0%) | 0% | 94.1 | 24,942 | Common Stock |
| Exact Sciences Corp | Paul J. Clancy | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 23 Mar 2026 | 20,640 | 5,398 (0%) | 0% | - | Common Stock | |
| Exact Sciences Corp | Paul J. Clancy | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 23 Mar 2026 | 5,398 | 0 (0%) | 0% | - | Common Stock | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 98.77 per share. | 31 Dec 2025 | 241 | 23,476 (0%) | 0% | 98.8 | 23,804 | Common Stock |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 84.81 per share. | 30 Sep 2025 | 285 | 23,235 (0%) | 0% | 84.8 | 24,171 | Common Stock |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 68.10 per share. | 30 Jun 2025 | 361 | 22,950 (0%) | 0% | 68.1 | 24,584 | Common Stock |
| Sionna Therapeutics Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 19,959 | 19,959 | - | - | Non-Qualified Stock Option (right to buy) | |
| Exact Sciences Corp | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 5,398 | 26,038 (0%) | 0% | 0 | Common Stock | |
| Xilio Therapeutics Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 31,000 | 31,000 | - | - | Stock Option (right to buy) | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 9,216 | 9,216 | - | - | Non Qualfied Stock Option (right to buy) | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 2,518 | 22,589 (0%) | 0% | 0 | Common Stock | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 60.55 per share. | 31 Mar 2025 | 358 | 20,071 (0%) | 0% | 60.6 | 21,677 | Common Stock |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 69.07 per share. | 31 Dec 2024 | 331 | 19,713 (0%) | 0% | 69.1 | 22,862 | Common Stock |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 66.10 per share. | 30 Sep 2024 | 368 | 19,382 (0%) | 0% | 66.1 | 24,325 | Common Stock |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 60.62 per share. | 28 Jun 2024 | 399 | 19,014 (0%) | 0% | 60.6 | 24,187 | Common Stock |
| Xilio Therapeutics Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Exact Sciences Corp | Paul Clancy J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,939 | 20,640 (0%) | 0% | 0 | Common Stock | |
| Exact Sciences Corp | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,444 | 20,145 (0%) | 0% | 0 | Common Stock | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 12,517 | 12,517 | - | - | Non Qualfied Stock Option (right to buy) | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,830 | 18,615 (0%) | 0% | 0 | Common Stock | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 56.97 per share. | 28 Mar 2024 | 403 | 15,785 (0%) | 0% | 57.0 | 22,959 | Common Stock |
| Incyte | Clancy J. Paul | Director | Grant, award, or other acquisition of securities at price $ 62.79 per share. | 29 Dec 2023 | 412 | 15,382 (0%) | 0% | 62.8 | 25,869 | Common Stock |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 62.25 per share. | 30 Jun 2023 | 380 | 14,591 (0%) | 0% | 62.3 | 23,655 | Common Stock |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 11,294 | 11,294 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 2,505 | 14,211 (0%) | 0% | 0 | Common Stock | |
| Xilio Therapeutics Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| Exact Sciences Corp | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 3,599 | 14,701 (0%) | 0% | 0 | Common Stock | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 72.27 per share. | 31 Mar 2023 | 318 | 11,706 (0%) | 0% | 72.3 | 22,982 | Common Stock |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 80.32 per share. | 30 Dec 2022 | 294 | 11,388 (0%) | 0% | 80.3 | 23,614 | Common Stock |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 66.64 per share. | 30 Sep 2022 | 339 | 11,094 (0%) | 0% | 66.6 | 22,591 | Common Stock |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 75.97 per share. | 30 Jun 2022 | 321 | 10,755 (0%) | 0% | 76.0 | 24,386 | Common Stock |
| Agios Pharma Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | |
| Agios Pharma Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | |
| Xilio Therapeutics Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 13,200 | 13,200 | - | - | Stock Option (right to buy) | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 9,124 | 9,124 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 2,144 | 10,434 (0%) | 0% | 0 | Common Stock | |
| Exact Sciences Corp | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 5,606 | 11,102 (0%) | 0% | 0 | Common Stock | |
| Agios Pharma Inc | Paul J. Clancy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| Agios Pharma Inc | Paul J. Clancy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 6,549 (0%) | 0% | 0 | Common stock | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 79.42 per share. | 31 Mar 2022 | 326 | 8,290 (0%) | 0% | 79.4 | 25,891 | Common Stock |
| Xilio Therapeutics Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2021 | 65,528 | 65,528 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2021 | 44,033 | 44,033 | - | - | Stock Option (right to buy) | |
| Incyte | Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 68.78 per share. | 30 Sep 2021 | 321 | 7,621 (0%) | 0% | 68.8 | 22,078 | Common Stock |